dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Fernández Montes, Ana |
dc.contributor.author | Alcaide, Julia |
dc.contributor.author | Alsina Maqueda, Maria |
dc.contributor.author | Custodio, Ana |
dc.contributor.author | Fernández Franco, Lourdes |
dc.contributor.author | Gallego Plazas, Javier |
dc.date.accessioned | 2022-08-12T06:31:17Z |
dc.date.available | 2022-08-12T06:31:17Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Fernández-Montes A, Alcaide J, Alsina M, Belén Custodio A, Fernández Franco L, Gallego Plazas J, et al. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clin Transl Oncol. 2022 Apr;24:658–69. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/7993 |
dc.description | Diagnosis; Esophageal cancer; Treatment |
dc.description.abstract | Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;24 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esòfag - Càncer - Tractament |
dc.subject | Immunoteràpia |
dc.subject | Esòfag - Càncer - Diagnòstic |
dc.subject.mesh | Esophageal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Immunotherapy |
dc.title | SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-022-02801-2 |
dc.subject.decs | neoplasias del esófago |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inmunoterapia |
dc.relation.publishversion | https://doi.org/10.1007/s12094-022-02801-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Fernández-Montes A] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. [Alcaide J] Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. [Alsina M] Medical Oncology Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Custodio AB] Medical Oncology Department, Hospital Universitario la Paz, CIBERONC Madrid, Spain. [Franco LF] Medical Oncology Department, Hospital Virgen de la Salud, Toledo, Spain. [Gallego Plazas J] Medical Oncology Department, Hospital General Universitario de Elche, Elche, Alicante, Spain |
dc.identifier.pmid | 35347573 |
dc.identifier.wos | 000773969100002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |